Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 10, 2003, Pages 1545-1550

  Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbonic anhydrase (CA); Obesity; Sulfamate; Topiramate

Indexed keywords

ACETAZOLAMIDE; ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; CARBONATE DEHYDRATASE INHIBITOR; CATECHOLAMINE DERIVATIVE; DEXFENFLURAMINE; DICLOFENAMIDE; ETHOXZOLAMIDE; FENFLURAMINE; METHAZOLAMIDE; METHYLCELLULOSE; PHENTERMINE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SULFONAMIDE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ANOREXIA; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; LIPOGENESIS; OBESITY; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 0242551296     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.10.1545     Document Type: Review

References (41)

1. FRIEDMAN JM: A war on obesity, not the obese. Science (2003) 299:856-859.
2. HILL JO, WYATT HR, REED GW, PETERS JC: Obesity and the environment: where do we go from here? Science (2003) 299:853-855.
3. HANIF MW, KUMAR S: Pharmacological management of obesity. Expert Opin. Pharmacother. (2002) 3:1711-1718.
4. SOJOSTROM L, RISANEN A, ANDERSEN T et al: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet (1998) 352:167-172.
5. DAVIDSON MH, HAUPTMAN J DIGIROLAMO M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA (1999) 281:235-242.
6. HOLLANDER PA, ELBEIN SC, HIRSCH IB et al.: Role of orlistat in the treatment of obese patients with Type 2 diabetes. Diabetes Care (1998) 21:1288-1294.
7. MCNELLY W, GOA KL: Sibutramine in obesity: a review. Drugs (1998) 56:1093-1124.
8. FUJIOKA K, SEATON TB, ROWE E et al.: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. (2000) 2:175-187.
9. SUPURAN CT, SCOZZAFAVA A, CASINI A: Carbonic anhydrase inhibitors. Med. Res. Rev. (2003) 23:146-189.
10. SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Patents (2000) 10:575-600.
11. SUPURAN CT, SCOZZAFAVA A: Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin. Ther. Patents (2002) 12:217-242.
12. HEWETT-EMMETT D: Evolution and distribution of the carbonic anhydrase gene families. In: The Carbonic Anhydrases-New Horizons. Chegwidden WM, Carter N, Edwards Y (Eds), Birkhäuser Verlag, Basel, Switzerland (2000):29-78.
13. DODGSON SJ: Inhibition of mitochondrial carbonic anhydrase: a discrepancy examined. J. Appl Physiol. (1987) 63:2134-2141.
14. DODGSON SJ, CHERIAN K: Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis. Am. J. Physiol. (1989) 257:E791-E796.
15. SPENCER IM, HARGREAVES I, CHEGWIDDEN WR: Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust. Biochem. Soc. Trans. (1988) 16:973-974.
16. CHEGWIDDEN WR, SPENCER IM: Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus. Comp. Biochem. Physiol. (1996) 115B:247-254.
17. CHEGWIDDEN WR, DODGSON SJ, SPENCER IM: The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals. In: The Carbonic Anhydrases-New Horizons. Chegwidden WR, Edwards Y, Carter N (Eds), Birkhäuser Verlag, Basel, Switzerland (2000):343-363.
18. LYNCH CJ, FOX H, HAZEN SA, STANLEY BA, DODGSON SJ, LANOUE KF: Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem. J. (1995) 310:197-202.
19. HAZEN SA, WAHEED A, SLY WS, LANOUE KF, LYNCH CJ: Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. FASEB J. (1996) 10:481-490.
20. ATWOOD PV: The structure and mechanism of action of pyruvate carboxylase. Int. J. Biochem. Cell Biol. (1995) 27:231-249.
21. ALLDRED JB, REILLY KE: Short-term regulation of acetyl CoA carboxylase in tissues of higher animals. Prog. Lipid Res. (1997) 35:371-385.
22. FORSTER RE, DODGSON SJ: Membrane transport and provision of substrates for carbonic anhydrase in vertebrates. In: The Carbonic Anhydrases - New Horizons. Chegwidden WR, Edwards Y, Carter N (Eds), Birkhäuser Verlag, Basel, Switzerland (2000):263-280.
23. PARKKILA S: An overview of the distribution and function of carbonic anhydrase isozymes in mammals. In: The Carbonic Anhydrases - New Horizons. Chegwidden WR, Edwards Y, Carter N (Eds), Birkhäuser Verlag, Basel, Switzerland (2000):79-94.
24. PARKKILA S, PARKKILA AK, KIVELÄ J: Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology. In: Carbonic anhydrase, its inhibitors and activators. Supuran CT, Scozzafava A, Conway J (Eds), Taylor & Francis, London & New York (2003) (In Press).
25. SHAH GN, HEWETT-EMMETT D et al.: Mitochondrial carbonic anhydrase CA VB: differences in tissue distribution and pattern of evolution from those of CA VA suggest distinct physiological roles. Proc. Nat Acad. Sci. USA (2000) 97:1677-1682.
26. SCOZZAFAVA A, MENABUONI L, MINCIONE F, BRIGANTI F, MINCIONE G, SUPURAN CT: Carbonic anhydrase inhibitors: Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action. J. Med. Chem. (2000) 43:4542-4551.
27. SUPURAN CT, BRIGANTI F, SCOZZAFAVA A: Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J. Enzyme Inhib. (1997) 12:175-190.
28. ILIES M, SUPURAN CT, SCOZZAFAVA A et al.: Carbonic anhydrase inhibitors. Sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorg. Med. Chem. (2000) 8:2145-2155.
29. ILIES MA, VULLO D, PASTOREK J et al.: Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX with halogenosulfanilamide and halogeno-aminophenylbenzolamide derivatives. J. Med. Chem. (2003) 46:2187-2196.
30. SCOZZAFAVA A, MENABUONI L, MINCIONE F, BRIGANTI F, MINCIONE G, SUPURAN CT: Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J. Med. Chem. (1999) 42:2641-2650.
31. SCOZZAFAVA A, BRIGANTI F, MINCIONE G, MENABUONI L, MINCIONE, F, SUPURAN CT: Carbonic anhydrase inhibitors: Synthesis of water-soluble, amino acyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J. Med. Chem. (1999) 42:3690-3700.
32. WINUM J-Y, VULLO D, CASINI A, MONTERO J-L, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: Inhibition of cytosolic isozymes I and II and the transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J. Med. Chem. (2003) 46:2197-2204.
33. SHANK RP, GARDOCKI JF, VAUGHT JL et al.: Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia (1994) 35:450-460.
34. EDMONDS HL, JIANG YD, ZHANG PY, SHANK RP: Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. Life Sci. (1996) 59:127-131.
35. STRINGER JL: A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res. (2000) 40:147-153.
36. SABERS A, GRAM L: Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs (2000) 60:23-33.
37. BOURGEOIS BFD: Pharmacokinetics and pharmacodynamics of topiramate. J. Child Neurol. (2000) 15S27-S30.
38. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: summary of the Fifth Eilat Conference. Epilepsy Res. (2001) 43:11-18.
39. GORDON A, PRICE LH: Mood stabilization and weight loss with topiramate. Am. J. Psychiatry (1999) 156:968-969.
40. PICARD F, DESHAIES Y, LALONDE J, SAMSON P, RICHARD D: Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obesity Res. (2000) 8:656-663.
41. CASINI A, ANTEL J, ABBATE F et al.: Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. (2003) 13:841-845.